Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
bp82
I think you can halve that!
$7.50/ADR - 2 shares /ADR. Shares /2 x $7.50=$735m or £520m
At £2/share we were priced around £392m, if one of the TILS pipeline treatments comes up trumps, it's valuation will be a minimum of £1b.
I don't believe TILS will be the same company in2028, depending on whether they've sold/partnered/joint ventured each success.
For those that are entitled or buy in one day, Acustem will probably be valued more than the 2028 speculation in the TILS research note.
Check out the charts 16th June -20th July. 17th Dec - 21st Jan. We appear to be at the start of the next rise. The last three rises have been walked back down. The next one could be a rerate and we stay higher.
Long term hold for me.
BB
Even after all these the broker has only given a target price of $7.50. Why? And that too in 2028. That only makes this co $1.4b worth.
And the co is beating drums like it will be $100 just after proof of concept.
Could someone more intelligent please shed some light.
The com
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_06242021_TLSA_Vandermosten.pdf
Worth a read re progress and developments.
Accoriding to the report...
Key reasons to own Tiziana shares:
? Multiple Phase II-ready assets pursuing unmet needs
o Fully human anti-CD3 - foralumab
? Multiple Sclerosis
? Crohn’s Disease
? COVID-19 / ARDS
o Pan-CDK inhibitor - milciclib
? Non-small cell lung carcinoma (NSCLC)
? Hepatocellular carcinoma (HCC)
o Fully human anti-IL-6 receptor – TZLS-501
? ARDS, ILD, COVID-19 and other diseases
? IND development underway
? Oral, nasal and inhaled administration of antibodies
o Improved ease of use
o No need for hospital-based infusion
o Lower doses required for efficacy
o Reduced systemic exposure and toxicity
o Fewer side effects with reduced systemic exposure and toxicity
o Focused distribution at the target organs in CD and severe lung disorders
o Higher lung drug retention and efficacy while minimising toxicity to other organs
? Validation of intranasal foralumab technology in Phase I COVID-19 trial
o Phase II trial announced
Their share target is $7.50 (currently $2.47).
I believe Tils have sposnored the report, although they state it is objective. Independent broker notes would be good going forward.
PS : AGM tomorrow